Oppenheimer Asset Management Inc. Decreases Position in Eidos Therapeutics Inc (NASDAQ:EIDX)

Oppenheimer Asset Management Inc. decreased its stake in Eidos Therapeutics Inc (NASDAQ:EIDX) by 14.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,210 shares of the company’s stock after selling 713 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Eidos Therapeutics were worth $131,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of Montreal Can boosted its position in shares of Eidos Therapeutics by 151.8% in the second quarter. Bank of Montreal Can now owns 1,385 shares of the company’s stock worth $43,000 after buying an additional 835 shares during the period. Alps Advisors Inc. purchased a new stake in shares of Eidos Therapeutics in the second quarter valued at $2,395,000. Swiss National Bank purchased a new stake in shares of Eidos Therapeutics in the second quarter valued at $426,000. SG Americas Securities LLC purchased a new stake in shares of Eidos Therapeutics in the second quarter valued at $125,000. Finally, Strs Ohio lifted its holdings in shares of Eidos Therapeutics by 457.1% in the second quarter. Strs Ohio now owns 11,700 shares of the company’s stock valued at $363,000 after purchasing an additional 9,600 shares in the last quarter. 32.46% of the stock is owned by institutional investors.

In other news, insider Jonathan C. Fox sold 15,000 shares of Eidos Therapeutics stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $40.04, for a total value of $600,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Uma Sinha sold 5,000 shares of Eidos Therapeutics stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $36.13, for a total transaction of $180,650.00. The disclosure for this sale can be found here. Insiders sold 30,000 shares of company stock valued at $1,171,700 in the last quarter. 70.10% of the stock is currently owned by corporate insiders.



Shares of NASDAQ:EIDX traded down $0.53 during midday trading on Friday, hitting $45.00. 223,700 shares of the stock were exchanged, compared to its average volume of 141,246. The company has a debt-to-equity ratio of 0.01, a quick ratio of 20.89 and a current ratio of 20.89. Eidos Therapeutics Inc has a 52-week low of $8.89 and a 52-week high of $46.99. The business’s fifty day simple moving average is $38.75 and its two-hundred day simple moving average is $29.92. The company has a market capitalization of $1.63 billion, a PE ratio of -24.19 and a beta of -0.99.

Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.01). As a group, equities analysts anticipate that Eidos Therapeutics Inc will post -1.7 EPS for the current year.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Eidos Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 23rd. Piper Jaffray Companies assumed coverage on Eidos Therapeutics in a report on Monday, July 22nd. They issued an “overweight” rating and a $55.00 target price for the company. BTIG Research increased their target price on Eidos Therapeutics to $56.00 and gave the company a “buy” rating in a report on Friday. Finally, BMO Capital Markets increased their target price on Eidos Therapeutics to $50.00 and gave the company an “outperform” rating in a report on Monday, July 22nd. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Eidos Therapeutics has a consensus rating of “Buy” and an average price target of $37.57.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Further Reading: What is an overbought condition?

Want to see what other hedge funds are holding EIDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eidos Therapeutics Inc (NASDAQ:EIDX).

Institutional Ownership by Quarter for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.